



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/654,428 | 09/04/2003 | Karen A. Ketchum | CL001013CIP-CON | 5367 |

25748 7590 10/18/2006

CELERA GENOMICS
ATTN: WAYNE MONTGOMERY, VICE PRES, INTEL PROPERTY
45 WEST GUDE DRIVE
C2-4#20
ROCKVILLE, MD 20850

| EXAMINER |
|----------|
|----------|

SEHARASEYON, JEGATHEESAN

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1647

DATE MAILED: 10/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | | |
|------------------------------|--|---------------------------------------|--|
| Office Action Summary | Application No. 10/654,428 | Applicant(s) KETCHUM ET AL. | |
| | Examiner Jegatheesan Seharaseyon, Ph.D | Art Unit 1647 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 July 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 12 and 14-16 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 12 and 14-16 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 04 September 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>9/4/2003</u> . | 6) <input checked="" type="checkbox"/> Other: <u>Appendix A & B</u> . |

DETAILED ACTION

1. Applicant's election without traverse of Group II, claim 12, drawn to polypeptide in the reply filed on 7/24/2006 is acknowledged. Applicant has elected to cancel claims 1-11 and 13 (Groups I and III) after amendments. Applicant has also added claims 14-16. Therefore, claims 12 and 14-16 are pending and under consideration.

Drawings

2. The drawings filed 9/4/2003 are acknowledged.

Information Disclosure Statement

3. The IDS submitted 9/4/2003 is acknowledged. Applicant has only provided abstracts of the WO documents listed. It is noted that the Office has considered the references to the extent of the provided abstract only. The listing of references in the Search Report is not considered to be an information disclosure statement (IDS) complying with 37 CFR 1.98. 37 CFR 1.98(a)(2) requires a legible copy of: (1) each foreign patent; (2) each publication or that portion which caused it to be listed; (3) for each cited pending U.S. application, the application specification including claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion, unless the cited pending U.S. application is stored in the Image File Wrapper (IFW) system; and (4) all other information, or that portion which caused it to be listed. In addition, each IDS must include a list of all patents, publications, applications, or other information submitted for

Art Unit: 1647

consideration by the Office (see 37 CFR 1.98(a)(1) and (b)), and MPEP § 609.04(a), subsection I. states, "the list ... must be submitted on a separate paper." Therefore, the references cited in the Search Report have not been considered. Applicant is advised that the date of submission of any item of information or any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the IDS, including all "statement" requirements of 37 CFR 1.97(e). See MPEP § 609.05(a).

Specification

4. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

5. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (see page 2). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 15 and 16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1647

6a. Claims 15 and 16 are indefinite because it is dependent on cancelled claims 1 and 2. Thus the metes and bounds of the claims are unclear. Therefore, claims 15 and 16 cannot be examined further because the Office is unable to determine the composition of the instant invention.

Claim Rejections - 35 USC § 101

7. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 12 and 14 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.

The instant claims are directed to a polypeptide comprising SEQ ID No: 2 belonging to an alleged human transporter protein. These claims are drawn to an invention with no apparent or disclosed patentable utility. The applicant claims that the protein of the invention is expressed in the breast based presumably on BLAST hits. In addition, based on tissue screening panels Applicant is able to show expression in breast and spleen (Figure 1B). The experimental data provided in Figure 1 includes the nucleotide sequence information, BLAST hit information and tissue screening panel information. There are no RNA or protein blots to indicate the expression profile. In addition, the instant application does not disclose the biological role of this protein or its

Art Unit: 1647

significance. Novel biological molecules lack well-established utility and must undergo extensive experimentation.

The Applicant claims that the human transporter protein sequence of the instant invention apparently encodes a 457 amino acid protein (Figure: 2) and contains structural features characteristic of monocarboxylate transporter protein (Figure: 2). This is presumably because of sequence homology between the instant invention (human transporter protein sequence) and other monocarboxylate transporter proteins. As seen in the enclosed Appendix the overall homology of the instant transporter protein to that of the prior art is 25% (see Appendix A1-A3). Further, the prior art teaches that the homology of a peptide is not a reliable indicator for the functional characteristics (see Scott et al. 1999). In the Scott et al. reference, based on the amino acid sequence homology it was predicted that the Pendred syndrome gene to be a sulfate transport protein. However, the results demonstrated that the protein was a chloride-iodide transporter protein (see abstract). Furthermore, since the specification does not disclose any methods or working examples that demonstrate the polynucleotide and polypeptide of the instant application exhibit activities similar to monocarboxylate transporter protein, the skilled artisan would not be able to categorize the polypeptide of the instant application as a transporter protein. Additionally, the specification of the instant application does not teach the skilled artisan which domains of transporter protein sequence are structurally related to other monocarboxylate transporter proteins. One skilled in the art would not know the utility and function of human transporter protein, even if it was a putative transporter protein because, as discussed in the related art

Art Unit: 1647

above and the specification of the instant application, neither the prior art nor the specification provides for the physiological significance of the claimed monocarboxylate transporter protein.

There is little doubt that, after complete characterization, this protein will probably be found to have a patentable utility. This further characterization, however, is part of the act of invention and, until it has been undertaken, Applicant's claimed invention is incomplete. The instant situation is directly analogous to that of which was addressed in *Brenner v. Manson*, 148 U.S.P.Q. 689 (Sus. Ct, 1966), in which a novel compound which was structurally analogous to other compounds which were known to possess anticancer activity was alleged to be potentially useful as an antitumor agent in the absence of evidence supporting this utility. The court expressed the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of "useful" as it appears in 35 U.S.C. 101, which required that an invention must have either an immediate obvious or fully disclosed "real-world" utility.

The court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility," "[u]nless and until a process is refined and developed to this point - where specific benefit exists in currently available form - there is insufficient justification for permitting an applicant to engross what may prove to be a broad field," and "a patent is not a hunting license," "[i]t is not a reward for the search, but compensation for its successful conclusion."

The instant claims are drawn to polypeptides, which have a yet undetermined function or biological significance. Applicants have disclosed that they are in possession of polypeptide SEQ ID NO: 2 encoded by nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3

Art Unit: 1647

(genomic sequence). In addition, Applicant also asserts the expression of the instant transporter cDNA in human breast and spleen tissues (page: 16). Applicant also indicates that this gene is located on human chromosome 17 (page: 22). However, there is no actual and specific significance which can be attributed to said polypeptides and the polynucleotides identified in the specification, except the prophetic recitation of potential uses, which include the use of this transporter protein and the nucleotides in screening assays, diagnosing a disease, raise antibodies, tissue markers, binding assays, transgenic animals etc. (pages: 26-62). Mere expression pattern data disclosed fails to indicate what monocarboxylate molecule is being transported or how the transporter is activated. In addition, the specification does not teach what monocarboxylate molecule are transported in which tissues by the claimed invention. Without this information, the skilled artisan would be unable to activate or inhibit the transporter or even know what physiological conditions this process would mediate. In fact Halestrap et al. disclose a monocarboxylate transporter (MCT13) that is located on human chromosome 17 and has 92% identity to the instant transporter, which is considered an "orphan transporter" (see Table 1 and Appendix B1-2). Halestrap et al. also disclose that there is no information is available on their properties or function. Further, there is no nexus with claimed invention and any disease or disorder. For this reason, the instant invention is incomplete. Since, neither the prior art nor the specification provides for the physiological significance of the disclosed and claimed receptor, there is no immediately obvious patentable use for it. In addition, the instant specification does not disclose a "real-world" use for said polypeptides and

Art Unit: 1647

polynucleotides, except the prophetic recitation of potential uses, which include possible biological and therapeutic uses. Also, there are no working examples that demonstrate any specific utility. Thus, the claimed invention is incomplete and, therefore, does not meet the requirements of 35 U.S.C. 101 as being useful. Therefore, since the peptide of the invention is not supported by a specific and substantial asserted utility or a well established utility, then the composition comprising the polypeptide and a carrier also are not supported by a specific and substantial asserted utility or a well established utility.

Claim Rejections - 35 USC § 112

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8a. Claims 12 and 14 are also rejected under 35 U.S.C. 112, first paragraph.

Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

8b. Claims 12 and 14 are rejected under 35 U.S.C. 112, first paragraph, because the specification were it enabling for polypeptide of SEQ ID NO: 2 as described in Figure 2A, does not reasonably provide enablement for all possible variants including fragments of SEQ ID NO: 2 contemplated by the Applicant. The claims recite the phrases "an amino acid sequence" and thus, are broadly interpreted by the Examiner

Art Unit: 1647

as reading upon: (i) protein variants with any number of deletions, substitutions, or additions and (ii) fragments of SEQ ID NO: 2, including sequences only 8 amino acids (see specification page 24-25). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention as claimed.

The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue. See *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404. The factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is “undue” include, but are not limited to: (1) the breadth of the claims; (2) the nature of the invention; (3) the state of the prior art; (4) the level of one of ordinary skill; (5) the level of predictability in the art; (6) the amount of direction provided by the inventor; (7) the existence of working examples; and (8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure.

The instant claims reads on polypeptide fragments of SEQ ID NO: 2. The claims also recite the phrases “an amino acid sequence” and thus, are broadly interpreted by the Examiner as reading upon: (i) protein variants with any number of deletions, substitutions, or additions and (ii) fragments of SEQ ID NOs: 2, including sequences only 8 amino acids in length (see specification page 24-25).

However, other than the polypeptide of SEQ ID NO: 2 (Figure 2A), the specification as filed fails to disclose any other amino acid sequence recited in the

Art Unit: 1647

instant claim. The specification does not teach functional or structural characteristics of the polypeptide variants, fragments, and derivatives encompassed by the claims.

Despite knowledge in the art for producing variant polypeptides, the specification fails to provide any guidance regarding the variant polypeptides by the contemplated methods that retain the function. Furthermore, detailed information regarding the structural and functional requirements of the disclosed protein is lacking. Although it is accepted that the amino acid sequence of a polypeptide determines its structural and functional properties, predicting a protein's structure and function from mere sequence data remains an elusive task. The problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein is extremely complex. While it is known that many amino acid substitutions are generally possible in any given protein the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions directly involved in binding, activity and in providing the correct three-dimensional spatial orientation of binding and active sites. These or other regions may also be critical determinants of antigenicity. These regions can tolerate only relatively conservative substitutions or no substitutions (see Wells, 1990, Biochemistry 29:8509-8517; Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495). However, Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue

Art Unit: 1647

experimentation, the positions in the protein which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. Although the specification outlines art-recognized procedures for producing and screening for active variants, this is not adequate guidance as to the nature of active derivatives that may be constructed, but is merely an invitation to the artisan to use the current invention as a starting point for further experimentation. Even if an active or binding site were identified in the specification, they may not be sufficient, as the ordinary artisan would immediately recognize that an active or binding site must assume the proper three-dimensional configuration to be active, which conformation is dependent upon surrounding residues; therefore substitution of non-essential residues can often destroy activity. Therefore, predicting which polypeptide, if any, would retain the functions of the protein is well outside the realm of routine experimentation. Further, since no function has been attributed to the claimed protein, the skilled artisan would not know what function to test for. Thus, an undue amount of experimentation would be required to generate the changes/modifications contemplated and yet retain the function of the proteins claimed.

Applicant has not taught how one of skill in the art would use the full scope of polypeptide sequences encompassed by the invention of claims 12 and 14. The specification as filed does not sufficiently teach one of skill in the art how to make and/or use the full scope of the claimed sequences. The amount of experimentation required to make and/or use the full scope of the claimed sequences would require trial and error experimentation to determine the functional sequences.

Given the breadth of claims 12 and 14 in light of the unpredictability of the art as determined by the lack of working examples and shown by the prior art of record, the level of skill of the artisan, and the lack of guidance provided in the instant specification, it would require undue experimentation for one of ordinary skill in the art to make and use the claimed invention.

8c. Claims 12 and 14 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. *This is a written description rejection.*

The specification discloses polypeptide sequence of SEQ ID NO: 2 (Figure 2A). This meets the written description provisions of 35 USC 112, first paragraph. However, the specification does not disclose all possible variants including fragments of SEQ ID NO: 2 contemplated by the Applicant. The claims recite the phrases "an amino sequence" and thus, are broadly interpreted by the Examiner as reading upon: (i) protein variants with any number of deletions, substitutions, or additions and (ii) fragments of SEQ ID NO: 2, including sequences only 8 amino acids in length (see specification page 24-25). The claims as written, however, encompass variant sequences which were not originally contemplated and fail to meet the written description provision of 35 USC 112, first paragraph because the written description is not commensurate in scope with the recitation of claims 12 and 14. The specification

Art Unit: 1647

does not provide written description to support the genus encompassed by the instant claims.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (See *Vas-Cath* at page 1116).

With the exception of isolated polypeptide sequence encoding SEQ ID NO: 2 (Figure: 2A), the skilled artisan cannot envision all the detailed chemical structure of the claimed polypeptide sequences of the variants regardless of the complexity or simplicity of the method of isolation.

Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The polypeptide itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016. One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481, 1483. In *Fiddes v. Baird*, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class.

Therefore, only the isolated polypeptide sequence of SEQ ID NO: 2 (Figure: 2A) but not the full breadth of the claims meets the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant. As a result, it does not appear that the inventors were in possession of various polypeptide sequences set forth in claims 12 and 14.

Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

Applicants are directed to the Revised Interim Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement, Federal Register, Vol. 64, No. 244, pages 71427-71440, Tuesday December 21, 1999.

Conclusion

9. No claims are allowed.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jegatheesan Seharaseyon, Ph.D whose telephone number is 571-272-0892. The examiner can normally be reached on M-F: 8:30-5:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

Application/Control Number: 10/654,428

Page 15

Art Unit: 1647

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JS

Art Unit 1647,
August 17, 2006

Geganeen Schanley
Patent Examiner
—